Treatment of chemotherapy-induced alopecia

Dermatologic Therapy

Volumn 24, Issue 4, 2011, Pages 432-442

  Yeager, Caroline E ^a   Olsen, Elise A ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

alopecia; chemotherapy; chemotherapy induced alopecia; hair loss treatment; permanent alopecia

Indexed keywords

ACETYLCYSTEINE; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTINEOPLASTIC AGENT; BUSULFAN; CALCITRIOL; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERGOCALCIFEROL; ESTRADIOL; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; IMUVERT; INTERLEUKIN 1; KERATINOCYTE GROWTH FACTOR; METHOTREXATE; MINOXIDIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DOXORUBICIN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANAGEN EFFLUVIUM; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COOLING; DRUG MEGADOSE; HAIR; HAIR COOLING; HAIR GROWTH; HAIR LOSS; HAIR SCARF; HUMAN; INDUCED HYPOTHERMIA; MEDULLOBLASTOMA; NEUTROPENIA; NONHUMAN; PATIENT COUNSELING; SCALP HYPOTHERMIA; SCALP METASTASIS; SCALP TOURNIQUET; SKIN METASTASIS; SYSTEMATIC REVIEW; TELOGEN EFFLUVIUM; THROMBOCYTOPENIA; TOURNIQUET; TURBAN; WIG;

ADMINISTRATION, TOPICAL; ALOPECIA; ANIMALS; ANTINEOPLASTIC AGENTS; HAIR; HUMANS; HYPOTHERMIA, INDUCED; MINOXIDIL; NEOPLASMS; SCALP;

EID: 80052715527     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01430.x     Document Type: Article

References (95)

1. Coates A, Abraham S, Kaye SB, et al,. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983: 19 (2): 203-208. (Pubitemid 13155858)
2. Baxley KO, Erdman LK, Henry EB, et al,. Alopecia: effect on cancer patients' body image. Cancer Nurs 1984: 7 (6): 499-503.
3. Kiebert GM, Hanneke J, de Haes CJ, et al,. Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. Eur J Cancer 1990: 26 (10): 1038-1042.
4. Sitzia J, Dikken C,. Survey of the incidence and severity of side-effects reported by patients receiving six cycles of FEC chemotherapy. J Cancer Nurs 1997: 1 (2): 61-73. (Pubitemid 127792251)
5. Sitzia J, Huggins L,. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract 1998: 6 (1): 13-21. (Pubitemid 28114033)
6. Lindley C, McCune JS, Thomason TE, et al,. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 1999: 7 (2): 59-65. (Pubitemid 29148608)
7. Carelle N, Piotto E, Bellanger A, et al,. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002: 95 (1): 155-163. (Pubitemid 34743494)
8. Duric VM, Stockler MR, Heritier S, et al,. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 2005: 16 (11): 1786-1794. (Pubitemid 41631241)
9. Lemieux J, Maunsell E, Provencher L,. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2008: 17 (4): 317-328. (Pubitemid 351513680)
10. Freedman TG,. Social and cultural dimensions of hair loss in women treated for breast cancer. Cancer Nurs 1994: 17 (4): 334-341. (Pubitemid 24255423)
11. Tierney AJ, Taylor J, Closs SJ,. Knowledge, expectations, and experiences of patients receiving chemotherapy for breast cancer. Scand J Caring Sci 1992: 6 (2): 75-80.
12. Browall M, Gaston-Johansson F, Danielson E,. Postmenopausal women with breast cancer: their experiences of the chemotherapy treatment period. Cancer Nurs 2006: 29 (1): 34-42. (Pubitemid 44309590)
13. Maunsell E, Brisson C, Dubois L, et al,. Work problems after breast cancer: an exploratoy qualitative study. Psychooncology 1999: 8 (6): 467-473. (Pubitemid 30014679)
14. Richer MC, Ezer H,. Living in it, living with it, and moving on: dimensions of meaning during chemotherapy. Oncol Nurs Forum 2002: 29 (1): 113-119.
15. Rosman S,. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 2004: 52 (3): 333-339. (Pubitemid 38283905)
16. Land SR, Kopec JA, Yothers G, et al,. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 2004: 86 (2): 153-164. (Pubitemid 38988018)
17. Bernard M, Brignone M, Adehossi A, et al,. Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study. Lung Cancer 2011: 72 (1): 114-118.
18. Hilton S, Hunt K, Emslie C, et al,. Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia. Psychooncology 2008: 17 (6): 577-583.
19. Olsen EA,. Chemotherapy-induced alopecia: overview and methodology for characterizing hair changes and regrowth. In:, Oliver IN, ed. The MASCC textbook of cancer supportive care and survivorship. New York, NY: Springer, 2011: 381-388.
20. American Cancer Society. Hair loss. Updated November 12, 2009. Accessed February 12, 2011.
21. Trueb RM,. Chemotherapy-induced alopecia. Semin Cutan Med Surg 2009: 28 (1): 11-14.
22. Grevelman EG, Breed WPM,. Prevention of chemotherapy-induced hair loss by scalp-cooling. Ann Oncol 2005: 16: 352-358. (Pubitemid 40458310)
23. Edelstyn GA, MacDonald M, MacRae KD,. Doxorubicin-induced hair loss and possible modification by scalp cooling. Lancet 1977: 2 (8031): 253-254. (Pubitemid 8120669)
24. Kennedy M, Packard R, Grant M, Padilla G, Presant C, Chillar R,. The effect of using Chemocap on occurrence of chemotherapy-induced alopecia. Oncol Nurs Forum 1983: 10 (1): 19-24.
25. Satterwhite B, Zimm S,. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 1984: 54 (1): 34-37. (Pubitemid 14117042)
26. Parker R,. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. Oncol Nurs Forum 1987: 14 (6): 49-53.
27. Giaccone G, Di Gulio F, Morandini MP, Calciati A,. Scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer Nurs 1988: 11 (3): 170-173.
28. Ron IG, Kalmus Y, Kalmus Z, Inbar M, Chaitchik S,. Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Support Care Cancer 1997: 5: 136-138. (Pubitemid 27163455)
29. Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H,. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur J Cancer Care (Engl) 2003: 12 (2): 154-161. (Pubitemid 37260168)
30. Lofti-Jam K, Carey M, Jefford M, et al,. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008: 26 (34): 5618-5629.
31. Peck HJ, Mitchell H, Stewart AL,. Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer. Eur J Oncol Nurs 2000: 4 (4): 246-248.
32. Ridderheim M, Bjurberg M, Gustavsson A,. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitalized scalp-cooling system used in 74 patients. Support Care Cancer 2003: 11 (6): 371-377. (Pubitemid 36734170)
33. Massey CS,. A multicentre study to determine the efficacy and patient acceptability of the Paxman scalp cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs 2004: 8 (2): 121-130. (Pubitemid 38811749)
34. Janssen FP, Rajan V, Steenbergen W, et al,. The relationship between local scalp temperature and cutaneous perfusion during scalp cooling. Physiol Meas 2007: 28 (8): 829-839. (Pubitemid 47421717)
35. Janssen FP, Bouten CV, van Leeuwen GM, et al,. Effects of temperature and doxorubicin exposure on keratinocyte damage in vitro. In Vitro Cell Dev Biol Anim 2008: 44 (3-4): 81-86.
36. Gregory RP, Cooke T, Middleton J, et al,. Prevention of doxorubicin-induced alopecia by scalp hypothermia: relation to degree of cooling. Br Med J (Clin Res Ed) 1982: 284 (6330): 1674. (Pubitemid 12109270)
37. Weiss S,. Sub-zero therapy lets a chemo patient keep her hair. The Washington Post. January 11, 2011; E1-E5.
38. Witman G, Cadman E, Chen M,. Letter: misuse of scalp hypothermia. Cancer Treat Rep 1981: 65: 507-508.
39. Forsberg S,. Letter: scalp cooling therapy and cytotoxic treatment. Lancet 2001: 357: 1134. (Pubitemid 32322562)
40. Lemenager M, Lecomte S, Bonneterre ME, et al,. Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 1997: 33: 297-300.
41. Lemieux J, Amireault C, Provencher L, et al,. Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat 2009: 118 (3): 547-552.
42. van de Sande MA, van den Hurk CJ, Breed WP, et al,. Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur. Ned Tijdschr Geneeskd 2010: 154 (33): A2134.
43. Simister JM,. Letter: alopecia and cytotoxic drugs. Br Med J 1966: 2 (5522): 1138.
44. Hennessy JD,. Letter: alopecia and cytotoxic drugs. Br Med J 1966: 2 (5522): 1138.
45. Pesce A, Cassuto JP, Audoly P,. Letter: scalp tourniquets in the prevention of chemotherapy-induced alopecia. N Engl J Med 1978: 298 (21): 1204-1205. (Pubitemid 8356497)
46. Soukop M, Campbell A, Gray MM, et al,. Letter: scalp tourniquet in cancer therapy. N Engl J Med 1978: 299 (11): 605-606. (Pubitemid 9058746)
47. Helson L, Prager D,. Letter: vincristine and alopecia. N Engl J Med 1971: 284 (6): 336.
48. O'Brien R, Zelson JH, Schwartz AD, et al,. Letter: scalp tourniquet to lessen alopecia after vincristine. N Engl J Med 1970: 283 (26): 1489.
49. Sredni B, Xu RH, Albeck M, et al,. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer 1996: 65 (1): 97-103.
50. Sredni B, Caspi RR, Klein A, et al,. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987: 330 (6144): 173-176. (Pubitemid 17158547)
51. Granai CO, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H,. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Eur J Gynaecol Oncol 1991: 12 (2): 129-132.
52. Rodriguez R, Machiavelli M, Leone B, et al,. Minoxidil (MX) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol 1994: 5 (8): 769-770. (Pubitemid 24302698)
53. Duvic M, Lemak NA, Valero V, et al,. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 1996: 35 (1): 74-78. (Pubitemid 26231327)
54. Hidalgo M, Rinaldi D, Medina G, et al,. A phase 1 trial of topical topitriol (calcitriol, 1, 25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs 1999: 10 (4): 393-395.
55. Hussein AM, Jimenez JJ, McCall CA, Yunis AA,. Protection from chemotherapy-induced alopecia in a rat model. Science 1990: 249 (4976): 1564-1566.
56. Paus R, Handjiski B, Eichmuller S, Czarnetzki BM,. Chemotherapy-induced alopecia in mice-induction by cyclophosphamide, inhibition by cyclosporine-A, and modulation by dexamethasone. Am J Pathol 1994: 144 (4): 719-734. (Pubitemid 24172061)
57. Hussein AM,. Chemotherapy-induced alopecia: new developments. South Med J 1993: 86 (5): 489-496. (Pubitemid 23150687)
58. Jimenez JJ, Wong GHW, Yunis AA,. Interleukin 1 protects from cytosine arabinoside-induced alopecia in a rat model. FASEB J 1991: 5 (10): 2456-2458. (Pubitemid 21905793)
59. Hussein AM,. Interleukin 1 protects against 1-beta-D- arabinofuranosylcytosine-induced alopecia in the newborn rat model. Cancer Res 1991: 51 (12): 3329-3330.
60. Jimenez JJ, Yunis AA,. Protection from 1-beta-D-arabinofuranosylcytosine- induced alopecia by epidermal growth factor and fibroblast growth factor in the rat model. Cancer Res 1992: 52 (2): 413-415.
61. Danilenko DM, Ring BD, Yanagihara D, et al,. Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation: normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia. Am J Pathol 1995: 147 (1): 145-154.
62. Balsari AL, Morelli D, Menard S, Veronesi U, Colnaghi MI,. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J 1994: 8 (2): 226-230.
63. Lutz G,. Effects of cyclosporin A on hair. Skin Pharmacol 1994: 7 (1-2): 101-104. (Pubitemid 24086201)
64. Hussein AM, Stuart A, Peters WP,. Protection against chemotherapy-induced alopecia by cyclosporine A in the newborn rat model. Dermatology 1995: 190 (3): 192-196.
65. Shirai A, Tsunoda H, Tamaoki T, Kamiya T,. Topical application of cyclosporin A induces rapid-remodeling of damaged anagen hair follicles produced in cyclophosphamide administered mice. J Dermatol Sci 2001: 27 (1): 7-13. (Pubitemid 32655422)
66. Ohnemus U, Unalan M, Handjiski B, Paus R,. Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to change. J Invest Dermatol 2004: 122 (1): 7-13. (Pubitemid 38114632)
67. Tallon B, Blanchard E, Goldberg LJ,. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 2010: 63 (2): 333-336.
68. Machado M, Moreb JS, Khan SA,. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007: 40 (10): 979-982. (Pubitemid 350048197)
69. Tosti A, Piraccini BM, Vincenzi C, et al,. Permanent alopecia after busulfan chemotherapy. Br J Dermatol 2005: 152 (5): 1056-1058. (Pubitemid 40704954)
70. de Jonge ME, Mathot RA, Dalesio O, et al,. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant 2002: 30 (9): 593-597. (Pubitemid 35414809)
71. Tran D, Sinclair RD, Schwarer AP, Chow CW,. Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol 2000: 41 (2): 106-108. (Pubitemid 30304005)
72. Ljungman P, Hassan M, Bekassy AN, et al,. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant 1995: 15 (6): 869-871.
73. Baker BW, Wilson CL, Davis AL, et al,. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair re-growth. Bone Marrow Transplant 1991: 7 (1): 43-47.
74. Vowels M, Chan LL, Giri N, et al,. Factors affecting hair regrowth after bone marrow transplantation. Bone Marrow Transplant 1993: 12 (4): 347-350. (Pubitemid 23295517)
75. Prevezas C, Matard B, Pinquier L, Reygagne P,. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 2009: 160 (4): 883-885.
76. Masidonski P, Mahon SM,. Permanent alopecia in women being treated for breast cancer. Clin J Oncol Nurs 2009: 13 (1): 13-14.
77. Sredni B, Gal R, Cohen IJ, et al,. Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. FASEB J 2004: 18 (2): 400-402.
78. Gleevec (package insert). East Hanover, NJ; Novartis Pharmaceuticals Co. 2009.
79. Sredni B, Albeck M, Tichler T, et al,. Bone marrow-sparing and prevention of alopecia by AS101 in non-small cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 1995: 13 (9): 2342-2353.
80. Hussein AM,. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int J Dermatol 1995: 34 (7): 470-473.
81. Jimenez JJ, Yunis AA,. Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res 1992: 52 (18): 5123-5125.
82. Jimenez JJ, Alvarez E, Bustamante CD, Yunis AA,. Pretreatment with 1,25(OH)2D3 protects from Cytoxan-induced alopecia without protecting the leukemic cells from Cytoxan. Am J Med Sci 1995: 310 (2): 43-47.
83. Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P,. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res 1996: 56 (19): 4438-4443. (Pubitemid 26330452)
84. Jimenez JJ, Yunis AA,. Vitamin D3 and chemotherapy-induced alopecia. Nutrition 1996: 12 (6): 448-449.
85. Schilli MB, Paus R, Menrad A,. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol 1998: 111 (4): 598-604. (Pubitemid 28452319)
86. Botchkarev VA, Komarova EA, Siebenhaar F, et al,. p53 is essential for chemotherapy-induced hair loss. Cancer Res 2000: 60 (18): 5002-5006.
87. Davis ST, Benson BG, Bramson HN, et al,. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001: 291 (5501): 134-137. (Pubitemid 32056682)
88. Davis ST, Benson BG, Bramson HN, et al,. Retraction. Science 2002: 298 (5602): 2327.
89. Tsuda T, Ohmori Y, Muramatsu H, et al,. Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia. Eur J Pharmacol 2001: 433 (1): 37-45. (Pubitemid 34038080)
90. Jimenez JJ, Roberts SM, Mejia J, et al,. Prevention of chemotherapy-induced alopecia in rodent models. Cell Stress Chaperones 2008: 13 (1): 31-38.
91. Jimenez JJ, Haung HS, Yunis AA,. Treatment with ImuVert/N-acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia. Cancer Invest 1992: 10 (4): 271-276.
92. D'Agostini F, Bagnasco M, Giunciuglio D, Albini A, De Flora S,. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol 1998: 13 (2): 217-224. (Pubitemid 28329207)
93. Peters EM, Foitzik K, Paus R, Ray S, Holick MF,. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001: 117 (2): 173-178. (Pubitemid 34205698)
94. Lacouture ME, Maitland ML, Segaert S, et al,. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010: 18 (4): 509-522.
95. National Cancer Institute. Cancer therapy evaluation program. common terminology criteria for adverse events (CTCAE) v4.0. Updated December 15, 2010. Accessed February 15, 2011.